Low levels of anti-cyclic citrullinated peptide (CCP) 3.1 associated with diseases other than rheumatoid arthritis

Our aim was to investigate the newest generation anti-cyclic citrullinated peptide (CCP) antibody 3.1 assay in diagnosing rheumatoid arthritis (RA) compared with other autoimmune and non-autoimmune diseases. We performed a retrospective observational chart review of patients with a positive CCP leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Son, James J., Ishimori, Mariko, Mirocha, James, Weisman, Michael H., Forbess, Lindsy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
6900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078438/
https://www.ncbi.nlm.nih.gov/pubmed/33879708
http://dx.doi.org/10.1097/MD.0000000000025558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078438/
https://www.ncbi.nlm.nih.gov/pubmed/33879708
http://dx.doi.org/10.1097/MD.0000000000025558

Ejemplares similares